{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:00:55Z","timestamp":1792098055144,"version":"4.4.0"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,11]]},"DOI":"10.1097\/icu.0b013e3282f03d42","type":"journal-article","created":{"date-parts":[[2007,10,12]],"date-time":"2007-10-12T03:01:31Z","timestamp":1192158091000},"page":"481-486","source":"Crossref","is-referenced-by-count":118,"title":["Biologics in the treatment of uveitis"],"prefix":"10.1097","volume":"18","author":[{"given":"Fraser R","family":"Imrie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D","family":"Dick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20210206","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1442-9071.2006.01225.x","article-title":"Biologic therapies for inflammatory eye disease","volume":"34","author":"Lim","year":"2006","journal-title":"Clin Experiment Ophthalmol"},{"key":"R2-8-20210206","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/bjo.2003.037192","article-title":"Anti-TNF-alpha therapy for sight threatening uveitis","volume":"89","author":"Lindstedt","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"R3-8-20210206","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.preteyeres.2004.06.005","article-title":"The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU)","volume":"23","author":"Dick","year":"2004","journal-title":"Prog Retin Eye Res"},{"key":"R4-8-20210206","first-page":"177","article-title":"Tumour necrosis factor-alpha-targeted therapies in uveitis","author":"Cochrane","year":"2007"},{"key":"R5-8-20210206","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/archopht.121.4.437","article-title":"Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate","volume":"121","author":"Foster","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"R6-8-20210206","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/art.20904","article-title":"A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis","volume":"53","author":"Smith","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R7-8-20210206","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S0012-3692(15)50471-6","article-title":"Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial","volume":"128","author":"Baughman","year":"2005","journal-title":"Chest"},{"key":"R8-8-20210206","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/j.ophtha.2006.04.038","article-title":"Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation","volume":"113","author":"Galor","year":"2006","journal-title":"Ophthalmology"},{"key":"R9-8-20210206","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1093\/rheumatology\/keh658","article-title":"Etanercept and uveitis in patients with juvenile idiopathic arthritis","volume":"44","author":"Schmeling","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"R10-8-20210206","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/rheumatology\/kel030","article-title":"Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis","volume":"45","author":"Saurenmann","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"R11-8-20210206","first-page":"1146","article-title":"Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey","volume":"34","author":"Foeldvari","year":"2007","journal-title":"J Rheumatol"},{"key":"R12-8-20210206","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1136\/ard.2006.052092","article-title":"Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study","volume":"65","author":"Guignard","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R13-8-20210206","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/art.21197","article-title":"Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the antitumor necrosis factor agents infliximab and etanercept","volume":"52","author":"Braun","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R14-8-20210206","first-page":"1362","article-title":"Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis","volume":"31","author":"Ohno","year":"2004","journal-title":"J Rheumatol"},{"key":"R15-8-20210206","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/sj.eye.6701689","article-title":"Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab)","volume":"19","author":"Benitez-del-Castillo","year":"2005","journal-title":"Eye"},{"key":"R16-8-20210206","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/archopht.123.7.903","article-title":"A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes","volume":"123","author":"Suhler","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"R17-8-20210206","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1002\/art.21231","article-title":"Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet's disease: an open-label trial","volume":"52","author":"Tugal-Tutkun","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R18-8-20210206","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ophtha.2005.09.037","article-title":"Retrospective case review of pediatric patients with uveitis treated with infliximab","volume":"113","author":"Rajaraman","year":"2006","journal-title":"Ophthalmology"},{"key":"R19-8-20210206","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.ophtha.2006.01.005","article-title":"Favorable response to high-dose infliximab for refractory childhood uveitis","volume":"113","author":"Kahn","year":"2006","journal-title":"Ophthalmology"},{"key":"R20-8-20210206","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10792-006-9006-9","article-title":"Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behcet's disease","volume":"26","author":"Abu El-Asrar","year":"2005","journal-title":"Int Ophthalmol"},{"key":"R21-8-20210206","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1442-9071.2005.01062.x","article-title":"Infliximab for juvenile idiopathic arthritis-associated uveitis","volume":"33","author":"Richards","year":"2005","journal-title":"Clin Experiment Ophthalmol"},{"key":"R22-8-20210206","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ajo.2006.10.047","article-title":"Successful treatment with infliximab in a patient with Diffuse Subretinal Fibrosis syndrome","volume":"143","author":"Adan","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"R23-8-20210206","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"R24-8-20210206","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/rheumatology\/keh584","article-title":"Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years","volume":"44","author":"Braun","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"R25-8-20210206","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/ard.2006.065441","article-title":"Use of infliximab in juvenile onset rheumatological disease associated refractory uveitis: efficacy in joint and ocular disease","volume":"66","author":"Sharma","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R26-8-20210206","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/bjo.2006.103721","article-title":"Adalimumab in the therapy of uveitis in childhood","volume":"91","author":"Biester","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R27-8-20210206","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jpeds.2006.04.058","article-title":"Adalimumab therapy for childhood uveitis","volume":"149","author":"Vazquez-Cobian","year":"2006","journal-title":"J Pediatr"},{"key":"R28-8-20210206","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/sj.eye.6702352","article-title":"Adalimumab for sight-threatening uveitis in Behcet's disease","volume":"21","author":"Mushtaq","year":"2007","journal-title":"Eye"},{"key":"R29-8-20210206","doi-asserted-by":"crossref","first-page":"7462","DOI":"10.1073\/pnas.96.13.7462","article-title":"Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I\/II clinical trial","volume":"96","author":"Nussenblatt","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R30-8-20210206","doi-asserted-by":"crossref","first-page":"593","DOI":"10.4321\/S0365-66912004001200004","article-title":"Recurrent uveitis and therapy with monoclonal antibody (daclizumab)","volume":"79","author":"Hernandez Garfella","year":"2004","journal-title":"Arch Soc Esp Oftalmol"},{"key":"R31-8-20210206","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.ophtha.2004.12.034","article-title":"Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series","volume":"112","author":"Nussenblatt","year":"2005","journal-title":"Ophthalmology"},{"key":"R32-8-20210206","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1136\/bjo.2006.0101477","article-title":"Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome","volume":"91","author":"Teoh","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R33-8-20210206","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/archopht.123.7.957","article-title":"Suppression of immune-mediated ocular inflammation in mice by interleukin 1 receptor antagonist administration","volume":"123","author":"Lim","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"R34-8-20210206","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1167\/iovs.06-0058","article-title":"Interferon-alpha: a key factor in autoimmune disease?","volume":"47","author":"Plskova","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R35-8-20210206","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1073\/pnas.0408506102","article-title":"Cross-regulation of TNF and IFN-alpha in autoimmune diseases","volume":"102","author":"Palucka","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R36-8-20210206","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/bjo.82.5.488","article-title":"Treatment of ocular symptoms of Behcet's disease with interferon alpha 2a: a pilot study","volume":"82","author":"Kotter","year":"1998","journal-title":"Br J Ophthalmol"},{"key":"R37-8-20210206","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/bjo.87.4.423","article-title":"Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis","volume":"87","author":"Kotter","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"R39-8-20210206","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/09273940490518865","article-title":"Interferon alpha-2a treatment for serpiginous choroiditis","volume":"13","author":"Sobaci","year":"2005","journal-title":"Ocul Immunol Inflamm"},{"key":"R40-8-20210206","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/bjo.2006.101550","article-title":"Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients","volume":"91","author":"Bodaghi","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R42-8-20210206","first-page":"S14","article-title":"Infliximab in refractory uveitis due to Behcet's disease","volume":"22","author":"Wechsler","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"R43-8-20210206","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1136\/bjo.2004.061119","article-title":"Interferon as a treatment for uveitis associated with multiple sclerosis","volume":"89","author":"Becker","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"R44-8-20210206","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1097\/01.iae.0000254891.48272.13","article-title":"Resolution of activity (choroiditis and choroidal neovascularization) of chronic recurrent punctate inner choroidopathy after treatment with interferon B-1A","volume":"26","author":"Cirino","year":"2006","journal-title":"Retina"},{"key":"R45-8-20210206","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/bjo.84.1.107","article-title":"Campath-1H therapy in refractory ocular inflammatory diseases","volume":"84","author":"Dick","year":"2000","journal-title":"Br J Ophthalmol"},{"key":"R46-8-20210206","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1136\/ard.2004.027128","article-title":"Successful treatment of refractory anterior scleritis in primary Sjorgen's syndrome with rituximab","volume":"64","author":"Ahmadi-Simab","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R47-8-20210206","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1136\/bjo.2005.075689","article-title":"Successful treatment of Wegener's granulomatosis associated scleritis with rituximab","volume":"89","author":"Cheung","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"R48-8-20210206","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.ajo.2004.04.066","article-title":"Infliximab for chronic cystoid macular edema associated with uveitis","volume":"138","author":"Markomichelakis","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"R49-8-20210206","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1097\/01.iae.0000244265.75771.71","article-title":"Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study","volume":"26","author":"Deuter","year":"2006","journal-title":"Retina"}],"container-title":["Current Opinion in Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/ICU.0b013e3282f03d42","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:51:14Z","timestamp":1786035074000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00055735-200711000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/icu.0b013e3282f03d42","relation":{},"ISSN":["1040-8738"],"issn-type":[{"value":"1040-8738","type":"print"}],"subject":[],"published":{"date-parts":[[2007,11]]}}}